Ignite Creation Date:
2025-12-24 @ 5:55 PM
Ignite Modification Date:
2026-02-03 @ 12:10 AM
Study NCT ID:
NCT04774068
Status:
COMPLETED
Last Update Posted:
2025-01-17
First Post:
2021-02-19
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell Lymphomas
Sponsor:
Walter Hanel
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Recurrent Anaplastic Large Cell Lymphoma | View |
| None | Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma | View |
| None | Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | View |
| None | Recurrent Transformed Mycosis Fungoides | View |
| None | Refractory Anaplastic Large Cell Lymphoma | View |
| None | Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma | View |
| None | Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | View |
| None | Refractory Transformed Mycosis Fungoides | View |
| None | T-Cell Non-Hodgkin Lymphoma | View |
Keywords: